FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1880573108> ?p ?o ?g. }

• W1880573108 endingPage "257" @default.
• W1880573108 startingPage "245" @default.
• W1880573108 abstract "As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of vedolizumab (Takeda UK) to submit evidence of the clinical effectiveness and cost effectiveness of vedolizumab for the treatment of patients with moderate-to-severe active ulcerative colitis (UC). The Evidence Review Group (ERG) produced a critical review of the evidence for the clinical effectiveness and cost effectiveness of the technology, based upon the company's submission to NICE. The evidence was derived mainly from GEMINI 1, a Phase 3, multicentre, randomised, double-blinded, placebo-controlled study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate-to-severe active UC with an inadequate response to, loss of response to or intolerance of conventional therapy or anti-tumour necrosis factor (TNF)-α. The clinical evidence showed that vedolizumab performed significantly better than placebo in both the induction and maintenance phases. In the post hoc subgroup analyses in patients with or without prior anti-TNF-α therapy, vedolizumab performed better then placebo (p value not reported). In addition, a greater improvement in health-related quality of life was observed in patients treated with vedolizumab, and the frequency and types of adverse events were similar in the vedolizumab and placebo groups, but the evidence was limited to short-term follow-up. There were a number of limitations and uncertainties in the clinical evidence base, which warrants caution in its interpretation--in particular, the post hoc subgroup analyses and high dropout rates in the maintenance phase of GEMINI 1. The company also presented a network meta-analysis of vedolizumab versus other biologic therapies indicated for moderate-to-severe UC. However, the ERG considered that the results presented may have underestimated the uncertainty in treatment effects, since fixed-effects models were used, despite clear evidence of heterogeneity among the trials included in the network. Results from the company's economic evaluation (which included price reductions to reflect the proposed patient access scheme for vedolizumab) suggested that vedolizumab is the most effective option compared with surgery and conventional therapy in the following three populations: (1) a mixed intention-to-treat population, including patients who have previously received anti-TNF-α therapy and those who are anti-TNF-α naïve; (2) patients who are anti-TNF-α naïve only; and (3) patients who have previously failed anti-TNF-α therapy only. The ERG concluded that the results of the company's economic evaluation could not be considered robust, because of errors in model implementation, omission of relevant comparators, deviations from the NICE reference case and questionable model assumptions. The ERG amended the company's model and demonstrated that vedolizumab is expected to be dominated by surgery in all three populations." @default.
• W1880573108 created "2016-06-24" @default.
• W1880573108 creator A5032796807 @default.
• W1880573108 creator A5037659831 @default.
• W1880573108 creator A5043984496 @default.
• W1880573108 creator A5051630157 @default.
• W1880573108 creator A5055996064 @default.
• W1880573108 creator A5061681421 @default.
• W1880573108 creator A5062779449 @default.
• W1880573108 creator A5070403975 @default.
• W1880573108 date "2015-10-17" @default.
• W1880573108 modified "2023-09-27" @default.
• W1880573108 title "Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal" @default.
• W1880573108 cites W1978842131 @default.
• W1880573108 cites W1984705525 @default.
• W1880573108 cites W1994618873 @default.
• W1880573108 cites W2002040688 @default.
• W1880573108 cites W2015352744 @default.
• W1880573108 cites W2020640954 @default.
• W1880573108 cites W2029703851 @default.
• W1880573108 cites W2029723826 @default.
• W1880573108 cites W2035914362 @default.
• W1880573108 cites W2046662922 @default.
• W1880573108 cites W2062766962 @default.
• W1880573108 cites W2070223602 @default.
• W1880573108 cites W2092863985 @default.
• W1880573108 cites W2100942700 @default.
• W1880573108 cites W2111287960 @default.
• W1880573108 cites W2117359708 @default.
• W1880573108 cites W2119864240 @default.
• W1880573108 cites W2120522488 @default.
• W1880573108 cites W2146692972 @default.
• W1880573108 cites W2162805528 @default.
• W1880573108 cites W2171297959 @default.
• W1880573108 cites W2237703297 @default.
• W1880573108 cites W4230633180 @default.
• W1880573108 cites W4295333203 @default.
• W1880573108 doi "https://doi.org/10.1007/s40273-015-0334-3" @default.
• W1880573108 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26477040" @default.
• W1880573108 hasPublicationYear "2015" @default.
• W1880573108 type Work @default.
• W1880573108 sameAs 1880573108 @default.
• W1880573108 citedByCount "15" @default.
• W1880573108 countsByYear W18805731082016 @default.
• W1880573108 countsByYear W18805731082017 @default.
• W1880573108 countsByYear W18805731082018 @default.
• W1880573108 countsByYear W18805731082019 @default.
• W1880573108 countsByYear W18805731082021 @default.
• W1880573108 countsByYear W18805731082022 @default.
• W1880573108 countsByYear W18805731082023 @default.
• W1880573108 crossrefType "journal-article" @default.
• W1880573108 hasAuthorship W1880573108A5032796807 @default.
• W1880573108 hasAuthorship W1880573108A5037659831 @default.
• W1880573108 hasAuthorship W1880573108A5043984496 @default.
• W1880573108 hasAuthorship W1880573108A5051630157 @default.
• W1880573108 hasAuthorship W1880573108A5055996064 @default.
• W1880573108 hasAuthorship W1880573108A5061681421 @default.
• W1880573108 hasAuthorship W1880573108A5062779449 @default.
• W1880573108 hasAuthorship W1880573108A5070403975 @default.
• W1880573108 hasBestOaLocation W18805731082 @default.
• W1880573108 hasConcept C112930515 @default.
• W1880573108 hasConcept C126322002 @default.
• W1880573108 hasConcept C142724271 @default.
• W1880573108 hasConcept C177713679 @default.
• W1880573108 hasConcept C199360897 @default.
• W1880573108 hasConcept C204787440 @default.
• W1880573108 hasConcept C27081682 @default.
• W1880573108 hasConcept C2776207728 @default.
• W1880573108 hasConcept C2779134260 @default.
• W1880573108 hasConcept C2779256446 @default.
• W1880573108 hasConcept C2780479503 @default.
• W1880573108 hasConcept C3019080777 @default.
• W1880573108 hasConcept C41008148 @default.
• W1880573108 hasConcept C64332521 @default.
• W1880573108 hasConcept C71924100 @default.
• W1880573108 hasConceptScore W1880573108C112930515 @default.
• W1880573108 hasConceptScore W1880573108C126322002 @default.
• W1880573108 hasConceptScore W1880573108C142724271 @default.
• W1880573108 hasConceptScore W1880573108C177713679 @default.
• W1880573108 hasConceptScore W1880573108C199360897 @default.
• W1880573108 hasConceptScore W1880573108C204787440 @default.
• W1880573108 hasConceptScore W1880573108C27081682 @default.
• W1880573108 hasConceptScore W1880573108C2776207728 @default.
• W1880573108 hasConceptScore W1880573108C2779134260 @default.
• W1880573108 hasConceptScore W1880573108C2779256446 @default.
• W1880573108 hasConceptScore W1880573108C2780479503 @default.
• W1880573108 hasConceptScore W1880573108C3019080777 @default.
• W1880573108 hasConceptScore W1880573108C41008148 @default.
• W1880573108 hasConceptScore W1880573108C64332521 @default.
• W1880573108 hasConceptScore W1880573108C71924100 @default.
• W1880573108 hasFunder F4320334661 @default.
• W1880573108 hasIssue "3" @default.
• W1880573108 hasLocation W18805731081 @default.
• W1880573108 hasLocation W18805731082 @default.
• W1880573108 hasLocation W18805731083 @default.
• W1880573108 hasOpenAccess W1880573108 @default.
• W1880573108 hasPrimaryLocation W18805731081 @default.
• W1880573108 hasRelatedWork W1593327399 @default.

• next